Incyte's early-stage JAK2V617F drug faces H2-2026 safety readout
INCB160058's Phase 1 trial will report dose-limiting toxicity and safety data in adults with myelofibrosis, polycythemia vera and essential thrombocythemia who failed prior therapy.
Executive Summary
- Incyte is heading toward a data disclosure for an early-stage inhibitor targeting a specific mutation found in most myeloproliferative neoplasms, with the readout testing tolerability rather than efficacy.
- The trial's completion timeline has moved out substantially since its original registration, while enrollment has grown in line with a standard early-phase expansion, and dosing of a new oral formulation only began earlier this year.
- No other clinical-stage program is targeting this specific mutation directly in this population, leaving the compound without an established benchmark from a comparable mechanism, while the broader myeloproliferative-neoplasm field is active with multiple later-stage, differently mechanized therapies.
- Because the trial cannot register a drug on its own, its main function is to determine whether the safety profile clears the bar needed to justify a larger, later-stage study.
The catalyst
Incyte said in its fourth-quarter and full-year 2025 earnings release that it anticipates results from the Phase 1 study of INCB160058 in patients with JAK2V617F-mutated myeloproliferative neoplasms in the second half of 2026. The trial, registered as NCT06313593, is testing the drug in adults with myelofibrosis, polycythemia vera, or essential thrombocythemia who have already failed at least one prior standard therapy, including a JAK inhibitor in the myelofibrosis cohort. The study's three primary endpoints are the number of participants with dose-limiting toxicities, the number with treatment-emergent adverse events leading to dose modification or discontinuation, and the overall incidence of treatment-emergent adverse events. That combination makes this a tolerability readout, not an efficacy one: it is designed to define a workable dose, not to demonstrate clinical benefit. Incyte+1Incyte Reports Fourth Quarter and Full Year 2025 Financial ResultsFeb 10, 2026A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsNCT06313593
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Where the program stands
Incyte disclosed separately that it began dosing an amorphous dispersion formulation of INCB160058 in the first quarter of 2026, an operational step that puts the trial on track to generate the safety data behind the guided readout. The trial has been recruiting since July 2024 and lists sites across the United States, Canada, and six European countries. Enrollment has grown from an original target of 66 participants to 144 in May 2025 and then to 186 in November 2025, alongside the trial's primary completion date shifting from June 2027 to March 2027 and then out to October 2028. Enrollment growth of this kind is standard for a Phase 1 dose-escalation study adding cohorts, and the current 186-participant target has held flat since November 2025, matching the operational model's routine range for early-phase trials. NCT06313593A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsNCT06313593
What the field looks like
No industry-sponsored trial in this indication targets JAK2V617F with a comparable mechanism, so INCB160058 has no direct comparator to benchmark its safety data against. The broader myeloproliferative-neoplasm field is active at later stages through mechanistically distinct programs, including PharmaEssentia's ropeginterferon alfa-2b in polycythemia vera, Merck's bomedemstat in essential thrombocythemia, and Takeda's elritercept and Geron's imetelstat in myelofibrosis, none of which share INCB160058's target. With no validated JAK2V617F-selective mechanism established in this setting, a safety profile clean enough to support dose expansion, without dose-limiting toxicities that curtail the regimen, would be the result that distinguishes this readout from a routine early-phase update.
Sponsor context
Incyte has run 470 total trials across its history, of which 193 have completed and 88 have terminated, and the company reports a 52% completion rate specifically in myeloproliferative neoplasms across 21 trials. That gives Incyte a demonstrated base of experience running trials in this disease area, even as this particular program's timeline has extended well beyond its original registration.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.